Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

NCT03627767 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1235

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis
Dermatitis, Atopic
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases

Interventions

DRUG: PF-04965842 100 mg
DRUG: PF-04965842 200 mg
DRUG: Placebo

Sponsor

Pfizer